# Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis

> **NCT01461317** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 121 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Etrolizumab

## Key facts

- **NCT ID:** NCT01461317
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11-29
- **Primary completion:** 2016-08-07
- **Final completion:** 2016-08-07
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2020-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01461317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01461317, "Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01461317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*